The Cancer Letter

Inside information on cancer research and drug development

Clinical

Trial: Erbitux-FOLFOX Therapy Improves PFS, OS in RAS Wild-Type Colorectal Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Results from a phase III trial of patients with metastatic colorectal cancer demonstrated that Erbitux (cetuximab) plus FOLFOX improved outcomes—including progression-free survival, overall survival and best overall response rate—when compared with FOLFOX alone.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

Study: Many don’t know alcohol, lack of exercise, high fat/processed foods are risk factors for colorectal cancer

A recent survey commissioned by the OSUCCC—James found that, while most U.S. adults identify family history (DNA-based risk passed down through families) as a risk factor for colorectal cancer, other factors such as alcohol use, lack of physical activity, and an American diet that is high in fat and processed foods were less known.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account